Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PPA

This article was originally published in The Tan Sheet

Executive Summary

Lawsuits against makers of PPA-containing cough/cold remedies, diet aids "involve common questions of fact" relating to ingredient's safety, Judicial Panel on Multidistrict Litigation says Aug. 28 in consolidating litigation. Panel transferred eight federal lawsuits filed in Louisiana, Massachusetts, Pennsylvania and Texas to a Seattle federal court, where Judge Barbara Rothstein will oversee coordinated pretrial proceedings. Most pending, future federal suits also will be transferred to Seattle. Defendants AHP, Bayer, BMS, Novartis, Schering and GlaxoSmithKline opposed centralization. Rothstein presides over six proposed consumer class actions relating to PPA (1"The Tan Sheet" March 5, p. 3)

Lawsuits against makers of PPA-containing cough/cold remedies, diet aids "involve common questions of fact" relating to ingredient's safety, Judicial Panel on Multidistrict Litigation says Aug. 28 in consolidating litigation. Panel transferred eight federal lawsuits filed in Louisiana, Massachusetts, Pennsylvania and Texas to a Seattle federal court, where Judge Barbara Rothstein will oversee coordinated pretrial proceedings. Most pending, future federal suits also will be transferred to Seattle. Defendants AHP, Bayer, BMS, Novartis, Schering and GlaxoSmithKline opposed centralization. Rothstein presides over six proposed consumer class actions relating to PPA (1 ).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel